News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Radhika Appaya

Articles by Radhika Appaya

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

ByRadhika Appaya,Sarah Sammons, MD,Priyanka Sharma, MD,Yara Abdou,VK Gadi, MD, PhD,Taavy A. Miller,Spencer S. Langerman,Dominick Latremouille-Viau,Annie Guerin,Carmine Rossi,Emily McGovern,Gary Sopher,Vamsi Bollu,Natalia Bolotova,Şerban R. Iorga,Liz Santarsiero,Susan Dent, MD

June 30th 2025

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

ByRadhika Appaya,Erika P. Hamilton, MD,Thomas Decker,Hope S. Rugo, MD,Maria Fernandez Abad,Kevin Kalinsky, MD, MS,Qiang Liu,Mariya Rozenblit, MD,Barbara Radecka,Seock-Ah Im,Frances Visco,Alejandro Perez,Yogesh Chattar,Murat Akdere,Vaidyanathan Ganapathy,Sorcha Waters,Joyce O’Shaughnessy, MD

June 27th 2025

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma

Giredestrant Exhibits DFS Improvement in Early-Stage Breast Cancer

NALIRIFOX Shows Survival Benefit Vs Gemcitabine/Nab-Paclitaxel in Metastatic PDAC

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

© 2025 MJH Life Sciences^®

All rights reserved.